TURBT术后吡柔比星灌注治疗对浅表性膀胱癌患者VEGF、FGF、MMPs及预后的影响

目的探讨尿道膀胱肿瘤电切术(TURBT)术后吡柔比星灌注治疗对浅表性膀胱癌患者血管内皮生长因子(VEGF)、成纤维细胞生长因子(FGF)、基质金属蛋白酶(MMPs)及预后的影响。方法选取2015年3月至2016年10月我院泌尿科收治的92例浅性膀胱癌患者,按照随机数字表法分为试验组(46例,TURBT+吡柔比星灌注治疗)与对照组(46例,TURBT)。比较两组患者治疗前、后的血清相关因子水平及预后情况。结果治疗后,两组的VEGF、a FGF、b FGF、MMP-2、MMP-9水平均降低,且试验组明显低于对照组,差异具有统计学意义(P<0.05)。治疗后24、36个月,试验组的生存率均显著高于对照组,差异具有统计学意义(P<0.05)。治疗后12、24、36个月,试验组的复发率均显著低于对照组,差异具有统计学意义(P<0.05)。试验组的不良反应总发生率为8.70%,明显低于对照组的23.91%,差异具有统计学意义(P<0.05)。结论浅表性膀胱癌患者TURBT术后吡柔比星灌注治疗,能够显著降低血清相关因子水平,改善预后效果,且安全性更高,值得临床推广应用。

Effects of pirarubicin infusion therapy after TURBT on VEGF,FGF, MMPs and prognosis in patients with superficial bladder cancer

Objective To investigate the effects of pirarubicin infusion therapy after transurethral resection of bladder tumors(TURBT) on vascular endothelial growth factor(VEGF),fibroblast growth factor(FGF),matrix metalloproteinases(MMPs) and prognosis in patients with superficial bladder cancer.Methods A total of 92 patients with superficial bladder cancer admitted in urology department of our hospital from March 2015 to October 2016 were selected and divided into experimental group(46 cases,TURBT+pirarubicin infusion therapy) and control group(46 cases,TURBT) according to the random number table method.The levels of serum related factors before and after treatment and prognosis between the two groups were compared.Results After treatment,the levels of VEGF,aFGF,bFGF,MMP-2 and MMP-9 of the two groups decreased,and those in the experimental group were significantly lower than the control group,the differences were statistically significant(P<0.05).At 24 and 36 months after treatment,the survival rates in the experimental group were significantly higher than those in the control group,the differences were statistically significant(P<0.05).At 12,24 and 36 months after treatment,the recurrence rates in the experimental group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the experimental group was8.70%,which was significantly lower than 23.91% in the control group,the difference was statistically significant(P<0.05).Conclusion Pirarubicin infusion therapy after TURBT in patients with superficial bladder cancer can significantly reduce the levels of serum related factors,improve the prognosis,and has higher safety.It is worthy of promotion and application.